Protagenic Therapeutics finishes enrollment and dosing for Phase 1 MAD study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Study Completion: Protagenic Therapeutics has completed enrollment and dosing in its Phase 1 study for the lead compound PT00114, which involved healthy volunteers.
Safety Assessment: The study aimed to evaluate the safety and tolerability of PT00114 after multiple doses over time.
Milestone Achievement: With all participants now dosed, the company has reached a significant milestone in the clinical development of its peptide-based therapeutic.
Results Timeline: Protagenic Therapeutics anticipates releasing top-line results from the study by November 30.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
